Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Atefeh Jafari, Hossein Khalili, Mandana Izadpanah & Simin Dashti-Khavidaki. (2015) Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection. Expert Opinion on Drug Safety 14:5, pages 713-731.
Read now
Read now
Articles from other publishers (55)
Charlotte Lanièce Delaunay, Marina B. Klein, Arnaud Godin, Joseph Cox, Nadine Kronfli, Bertrand Lebouché, Carla Doyle & Mathieu Maheu-Giroux. (2023) Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study. International Journal of Drug Policy 116, pages 104026.
Crossref
Crossref
Prateek Lohia, Shweta Kapur & Lawrence Crane. (2022) A Comprehensive Hepatitis C Treatment Program—An Observational Study of Collaboration Between Infectious Disease Specialists and General Internal Medicine Provider Serving a Majority Black Population. Infectious Diseases in Clinical Practice 30:6.
Crossref
Crossref
Charlotte Lanièce Delaunay, Arnaud Godin, Nadine Kronfli, Dimitra Panagiotoglou, Joseph Cox, Michel Alary, Marina B. Klein & Mathieu Maheu-Giroux. (2021) Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. International Journal of Drug Policy 96, pages 103343.
Crossref
Crossref
Nirmal Kumar, Suchitra S. Prabhu, Isha Monga & Indranil Banerjee. (2021) Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. Meta Gene 29, pages 100909.
Crossref
Crossref
Talia Sainz, Carolina Fernández McPhee, Sara Domínguez‐Rodríguez, Loreto Hierro, María José Mellado, Claudia Fortuny, María Dolores Falcón, Pere Soler‐Palacín, Pablo Rojo, José Tomás Ramos, César Gavilán, Carmelo Guerrero, Maria del Carmen Díaz, Paloma Jara & María Luisa Navarro. (2019) Longitudinal evolution of vertically HIV/HCV–co‐infected vs HCV–mono‐infected children. Journal of Viral Hepatitis 27:1, pages 61-67.
Crossref
Crossref
Jingjing Wu, Peng Huang, Haozhi Fan, Ting Tian, Xueshan Xia, Zuqiang Fu, Yan Wang, Xiangyu Ye, Ming Yue & Yun Zhang. (2019) Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis. Virology Journal 16:1.
Crossref
Crossref
Y. Li, S. Li, X. Duan, C. Yang, M. Xu & L. Chen. (2018) Hepatitis C: from discovery to cure. ISBT Science Series 13:3, pages 244-251.
Crossref
Crossref
B. Rossetti, F. Bai, A. Tavelli, M. Galli, A. Antinori, F. Castelli, G. Pellizzer, A. Cozzi-Lepri, S. Bonora, A.d'Arminio Monforte, M. Puoti & A. De Luca. (2018) Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clinical Microbiology and Infection 24:4, pages 422-427.
Crossref
Crossref
Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Amr Menshawy, Attia Attia, Arwa Mohamed, Ahmed Negida & Mohamed M. Abdel-Daim. (2018) Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. Annals of Hepatology 17:1, pages 18-32.
Crossref
Crossref
Michael W. Fried, Jama M. Darling & Stanley M. Lemon. 2017. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
628
698
.
Debika Bhattacharya, Pamela S. Belperio, Troy A. Shahoumian, Timothy P. Loomis, Matthew B. Goetz, Larry A. Mole & Lisa I. Backus. (2017) Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1–Coinfected Patients Treated in Routine Practice. Clinical Infectious Diseases 64:12, pages 1711-1720.
Crossref
Crossref
L Milazzo, A Lai, E Calvi, P Ronzi, V Micheli, F Binda, AL Ridolfo, C Gervasoni, M Galli, S Antinori & S Sollima. (2016)
Direct‐acting antivirals in hepatitis C virus (
HCV
)‐infected and
HCV
/
HIV
‐coinfected patients: real‐life safety and efficacy
. HIV Medicine 18:4, pages 284-291.
Crossref
Crossref
Irina Magdalena Dumitru, Eugen Dumitru, Liliana Ana Tuta & Sorin Rugina. (2017) Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients. ARS Medica Tomitana 23:1, pages 47-52.
Crossref
Crossref
Yinan Yao, Ming Yue, Jie Wang, Hongbo Chen, Mei Liu, Feng Zang, Jun Li, Yun Zhang, Peng Huang & Rongbin Yu. (2017) Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis. Canadian Journal of Gastroenterology and Hepatology 2017, pages 1-7.
Crossref
Crossref
Philip Vutien, Joseph Hoang, Louis Brooks, Nghia H. Nguyen & Mindie H. Nguyen. (2016) Racial Disparities in Treatment Rates for Chronic Hepatitis C. Medicine 95:22, pages e3719.
Crossref
Crossref
Mark Hull, Stephen Shafran, Alex Wong, Alice Tseng, Pierre Giguère, Lisa Barrett, Shariq Haider, Brian Conway, Marina Klein & Curtis Cooper. (2016) CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Canadian Journal of Infectious Diseases and Medical Microbiology 2016, pages 1-34.
Crossref
Crossref
Maria Luisa Montes, Mark Nelson, Pierre-Marie Girard, Joe Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia Zakharova, Antonio Rivero, Jacques Durant, Enrique Ortega-Gonzalez, Erkki Lathouwers, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, James Witek & Juan González-García. (2016) Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. Journal of Antimicrobial Chemotherapy 71:1, pages 244-250.
Crossref
Crossref
Frank Andersohn, Anne-Kathrin Claes, Werner Kulp, Jörg Mahlich & Jürgen Kurt Rockstroh. (2016) Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison. BMC Infectious Diseases 16:1.
Crossref
Crossref
Joop E. Arends, Faydra I. Lieveld, Lauke L. Boeijen, Clara T.M.M. de Kanter, Karel J. van Erpecum, Dominique Salmon, Andy I.M. Hoepelman, Tarik Asselah & Andrew Ustianowski. (2015) Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?. Journal of Hepatology 63:5, pages 1254-1262.
Crossref
Crossref
Giuseppe Indolfi, Elisa Bartolini, Daniele Serranti, Chiara Azzari & Massimo Resti. (2015) Hepatitis C in Children Co-infected With Human Immunodeficiency Virus. Journal of Pediatric Gastroenterology & Nutrition 61:4, pages 393-399.
Crossref
Crossref
Stephen D. Shafran. (2015) HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clinical Infectious Diseases 61:7, pages 1127-1134.
Crossref
Crossref
Anna Turkova, Vania Giacomet, Tessa Goetghebuer, Milana Miloenko, Laura Ambra Nicolini, Antoni Noguera-Julian, Pablo Rojo, Alla Volokha, Giuseppe Indolfi, Carlo Giaquinto & Claire Thorne. (2015) HCV treatment in children and young adults with HIV/HCV co-infection in Europe. Journal of Virus Eradication 1:3, pages 179-184.
Crossref
Crossref
Maribel Rodriguez-Torres, Anuj Gaggar, Gong Shen, Brian Kirby, Evguenia Svarovskaia, Diana Brainard, William T. Symonds, John G. McHutchison, Milagros Gonzalez & Jose Rodriguez-Orengo. (2015) Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 68:5, pages 543-549.
Crossref
Crossref
Kristine R Broglio, Eric S Daar, Melanie Quintana, Yong Yuan, Anupama Kalsekar, Brad Spellberg, Roger J Lewis, Dane van den Akker, Michelle A Detry, Trong Le & Scott M Berry. (2015) A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. Journal of Comparative Effectiveness Research 4:2, pages 101-114.
Crossref
Crossref
Mattias Mandorfer, Sebastian Steiner, Philipp Schwabl, Berit A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina Grabmeier-Pfistershammer, Michael Trauner, Markus Peck-Radosavljevic & Thomas Reiberger. (2015) Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. The Journal of Infectious Diseases 211:5, pages 729-735.
Crossref
Crossref
Mark Sulkowski, Christophe Hezode, Jan Gerstoft, John M Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo, Nina Weis, Ronald Nahass, Oren Shibolet, Lawrence Serfaty, Marc Bourliere, Edwin DeJesus, Eli Zuckerman, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita Y M Howe, Janice Wahl, Michael Robertson, Eliav Barr & Barbara Haber. (2015) Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. The Lancet 385:9973, pages 1087-1097.
Crossref
Crossref
Caterina Sagnelli. (2015) Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World Journal of Hepatology 7:24, pages 2510.
Crossref
Crossref
Noboru Hirashima, Hiroaki Iwase, Masaaki Shimada, Junji Imamura, Wataru Sugiura, Yoshiyuki Yokomaku & Tsunamasa Watanabe. (2015) An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin. Internal Medicine 54:17, pages 2173-2177.
Crossref
Crossref
L. Cotte, J. Braun, C. Lascoux-Combe, C. Vincent, M.-A. Valantin, P. Sogni, K. Lacombe, D. Neau, H. Aumaitre, D. Batisse, P. de Truchis, A. Gervais, C. Michelet, P. Morlat, D. Vittecoq, I. Rosa, I. Bertucci, S. Chevaliez, J.-P. Aboulker, J.-M. Molina, H. Aumaitre, D. Batisse, L. Bernard, A. Cheret, L. Cotte, P. de Truchis, P. Dellamonica, S. Dominguez, A. Gervais, P.-M. Girard, F. Lucht, S. Metivier, C. Michelet, J.-M. Molina, P. Morlat, D. Neau, G. P. Pageaux, S. Pol, I. Rosa, E. Rosenthal, D. Vittecoq, M.-A. Valantin & D. Zucman. (2014) Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial. Clinical Infectious Diseases 59:12, pages 1768-1776.
Crossref
Crossref
Douglas Dieterich, Jürgen Kurt Rockstroh, Chloe Orkin, Félix Gutiérrez, Marina B. Klein, Jacques Reynes, Umesh Shukla, Alan Jenkins, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Monika Peeters, Guy De La Rosa, Lotke Tambuyzer & Wolfgang Jessner. (2014) Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. Clinical Infectious Diseases 59:11, pages 1579-1587.
Crossref
Crossref
Stanislas Pol & Anais Vallet-Pichard. (2014) Optimal Management of HIV-HCV Coinfection. Current Hepatology Reports 13:4, pages 295-303.
Crossref
Crossref
Mark S. Sulkowski. (2014) Management of acute and chronic HCV infection in persons with HIV coinfection. Journal of Hepatology 61:1, pages S108-S119.
Crossref
Crossref
J Slim, N Scangarello, P Samaha & J Dazley. (2014) A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease. International Journal of STD & AIDS 25:11, pages 830-832.
Crossref
Crossref
Cassandra B. Jabara, Fengyu Hu, Katie R. Mollan, Sara E. Williford, Prema Menezes, Yan Yang, Joseph J. Eron, Michael W. Fried, Michael G. Hudgens, Corbin D. Jones, Ronald Swanstrom & Stanley M. Lemon. (2014) Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. Antimicrobial Agents and Chemotherapy 58:10, pages 6079-6092.
Crossref
Crossref
Sammy Saab, Christian Jackson, Jose Nieto & Fritz Francois. (2014) Hepatitis C in African Americans. American Journal of Gastroenterology 109:10, pages 1576-1584.
Crossref
Crossref
Lindsay A. Petty, Jennifer L. Steinbeck, Kenneth Pursell & Donald M. Jensen. (2014) Human Immunodeficiency Virus and Coinfection with Hepatitis B and C. Infectious Disease Clinics of North America 28:3, pages 477-499.
Crossref
Crossref
Jennifer Y. Chen, Eoin R. Feeney & Raymond T. Chung. (2014) HCV and HIV co-infection: mechanisms and management. Nature Reviews Gastroenterology & Hepatology 11:6, pages 362-371.
Crossref
Crossref
Mattias Mandorfer, Karin Neukam, Antonio Rivero, Massimo Puoti, Christoph Boesecke, Axel Baumgarten, Anna Grzeszczuk, Robert Zangerle, Diana Ernst, Jürgen Kurt Rockstroh, Michael Trauner, Juan Antonio Pineda, Markus Peck-Radosavljevic & Thomas Reiberger. (2013) Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. Antiviral Therapy 19:4, pages 407-414.
Crossref
Crossref
Mattias MandorferBerit A. PayerAlexander NiedereckerGerold LangMaximilian C. AichelburgRobert StrasslChristoph BoeseckeArmin RiegerMichael TraunerMarkus Peck-RadosavljevicThomas Reiberger. (2014) Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. AIDS Patient Care and STDs 28:5, pages 221-227.
Crossref
Crossref
Masayuki Murata, Norihiro Furusyo, Eiichi Ogawa, Fujiko Mitsumoto, Satoshi Hiramine, Hiroaki Ikezaki, Koji Takayama, Motohiro Shimizu, Kazuhiro Toyoda, Mosaburo Kainuma & Jun Hayashi. (2014) A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Journal of Infection and Chemotherapy 20:5, pages 320-324.
Crossref
Crossref
Clara T. M. M. de Kanter, Joost P. H. Drenth, Joop E. Arends, Henk W. Reesink, Marc van der Valk, Robert J. de Knegt & David M. Burger. (2014) Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics 53:5, pages 409-427.
Crossref
Crossref
. (2014) EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 60:2, pages 392-420.
Crossref
Crossref
Barbara Coco, Paolo Caraceni, Alessio Aghemo, Davide Bitetto, Raffaele Bruno, Alessia Ciancio, Marco Marzioni, Salvatore Petta, Maria Rendina, Luca Valenti, Alfredo Alberti, Pietro Andreone, Ferruccio Bonino, Maurizia R. Brunetto, Savino Bruno, Massimo Colombo, Antonio Craxì, Giovanni B. Gaeta, Alessandra Mangia, Massimo Puoti, Mario Rizzetto & Maria Grazia Rumi. (2014) Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 46:1, pages 18-24.
Crossref
Crossref
Jürgen K Rockstroh & Sanjay Bhagani. (2013) Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Medicine 11:1.
Crossref
Crossref
G. N. Ioannou, J. D. Scott, Y. Yang, P. K. Green & L. A. Beste. (2013) Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Alimentary Pharmacology & Therapeutics 38:11-12, pages 1373-1384.
Crossref
Crossref
Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg & Geoffrey M. Dusheiko. (2013) Treatment decisions and contemporary versus pending treatments for hepatitis C. Nature Reviews Gastroenterology & Hepatology 10:12, pages 713-728.
Crossref
Crossref
Cody A. Chastain & Susanna Naggie. (2013) Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. Current HIV/AIDS Reports 10:4, pages 408-419.
Crossref
Crossref
Massimo Puoti, Roberto Rossotti, Giovanna Travi, Claudia Panzeri, Marco Morreale, Erika Chiari, Giorgia Cocca, Maurizio Orso & Maria Cristina Moioli. (2013) Optimizing treatment in HIV/HCV coinfection. Digestive and Liver Disease 45, pages S355-S362.
Crossref
Crossref
Mark Sulkowski, Stanislas Pol, Josep Mallolas, Hugo Fainboim, Curtis Cooper, Jihad Slim, Antonio Rivero, Carmen Mak, Seth Thompson, Anita YM Howe, Larissa Wenning, Peter Sklar, Janice Wahl & Wayne Greaves. (2013) Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet Infectious Diseases 13:7, pages 597-605.
Crossref
Crossref
N. Gara & M. G. Ghany. (2013) What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. Clinical Infectious Diseases 56:11, pages 1629-1636.
Crossref
Crossref
Masao Omata & Tatsuo KandaPhilippe SogniMarion CorougeStanislas Pol. 2013. Emerging Therapeutic Options for Hepatitis C. Emerging Therapeutic Options for Hepatitis C
58
71
.
M. S. Sulkowski. (2013) Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. Journal of Infectious Diseases 207:suppl 1, pages S26-S32.
Crossref
Crossref
Mark S. Sulkowski. (2013) HCV therapy in HIV-infected patients. Liver International 33, pages 63-67.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Infectious Diseases 25:6, pages 718-728.
Crossref
Crossref
Mark S. Sulkowski. (2012) Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. Clinical Liver Disease 1:3, pages 69-72.
Crossref
Crossref